ravn Årsrapport 2015 141016 trykk pk - folkehelseinstituttet · ravn 2015 • norwegian institute...
TRANSCRIPT
www.fhi.no
Published by Norwegian Institute of Public HealthSeptember 2016P. O. Box 4404 NydalenNO-0403 OsloTel: 21 07 70 00
Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2015
RAVNResistensovervåking av virus i Norge Resistance against Antivirals in Norway
2016
RAVN 2015 omslag.indd 1 14.10.2016 15.39
RAVN 2015 • Norwegian Institute of Public Health
2
PublishedbyNorwegianInstituteofPublicHealthSeptember2016
Title:UsageofAntiviralsandtheOccurrenceofAntiviralResistanceinNorway2015.RAVN
Ordering:Electroniccopy(PDF):www.fhi.no/en/publ/www.fhi.no/publPrintedcopycanbeorderedfrom:NorwegianInstituteofPublicHealthP.O.Box4404NydalenNO-0403Oslopublikasjon@fhi.noTel:+4721078200
Coverdesign:PerKristianSvendsen/GreteSøimer
Printedcopies:500
CoverPhoto:Colourbox.comISBN978-82-8082-769-2(printedcopy)ISBN978-82-8082-770-8(electroniccopy)
RAVN 2015 • Norwegian Institute of Public Health
3
RAVN 2015 • Norwegian Institute of Public Health
4
Anita Kanestrøm RAVN, Norwegian Institute of Public Health (NIPH)
RAVN 2015 • Norwegian Institute of Public Health
5
RAVN 2015 • Norwegian Institute of Public Health
6
RAVN 2015 • Norwegian Institute of Public Health
7
RAVN 2015 • Norwegian Institute of Public Health
8
RAVN 2015 • Norwegian Institute of Public Health
9
RAVN 2015 • Norwegian Institute of Public Health
10
RAVN 2015 • Norwegian Institute of Public Health
11
RAVN 2015 • Norwegian Institute of Public Health
12
RAVN 2015 • Norwegian Institute of Public Health
13
RAVN 2015 • Norwegian Institute of Public Health
14
RAVN 2015 • Norwegian Institute of Public Health
15
www.norpd.no
RAVN 2015 • Norwegian Institute of Public Health
16
RAVN 2015 • Norwegian Institute of Public Health
17
RAVN 2015 • Norwegian Institute of Public Health
18
http://ecdc.europa.eu/en/publications/Publications/neuraminidase-inhibitors-flu-consultation.pdf
RAVN 2015 • Norwegian Institute of Public Health
19
RAVN 2015 • Norwegian Institute of Public Health
20
RAVN 2015 • Norwegian Institute of Public Health
21
http://www.unaids.org/en/resources/campaigns/HowAIDSchangedeverything/factsheet
RAVN 2015 • Norwegian Institute of Public Health
22
RAVN 2015 • Norwegian Institute of Public Health
23
https://www.kvalitetsregistre.no/registers/557/resultater/556
RAVN 2015 • Norwegian Institute of Public Health
24
RAVN 2015 • Norwegian Institute of Public Health
25
RAVN 2015 • Norwegian Institute of Public Health
26
RAVN 2015 • Norwegian Institute of Public Health
27
RAVN 2015 • Norwegian Institute of Public Health
28
RAVN 2015 • Norwegian Institute of Public Health
29
RAVN 2015 • Norwegian Institute of Public Health
30
RAVN 2015 • Norwegian Institute of Public Health
31
RAVN 2015 • Norwegian Institute of Public Health
32
RAVN 2015 • Norwegian Institute of Public Health
33
RAVN 2015 • Norwegian Institute of Public Health
34
RAVN 2015 • Norwegian Institute of Public Health
35
RAVN 2015 • Norwegian Institute of Public Health
36
RAVN 2015 • Norwegian Institute of Public Health
37
RAVN 2015 • Norwegian Institute of Public Health
38
RAVN 2015 • Norwegian Institute of Public Health
39
RAVN 2015 • Norwegian Institute of Public Health
40
Johan Lennerstrand, Associate professor Clinical Microbiology, Department of Medical Sciences, Uppsala University Hospital [email protected], 18.08.2016
RAVN 2015 • Norwegian Institute of Public Health
41
RAVN 2015 • Norwegian Institute of Public Health
42
NDA No data available *Prevalence of 5 - 10% at baseline for DAA treatment naive patients when using Sanger sequencing method (20% cut-off). ** Natural NS3 polymorphism of 100% at baseline for genotype 3
NDA No data available *Prevalence of 5 - 10% at baseline for DAA treatment naive patients when using Sanger sequencing method (20% cut-off). Table 1 and 2 references: Lontok et al, Hepatology 2015 ; Sarrazin, J Hepatology 2016 ; Wyles D, AASLD presentation 2015 ; NG T et al, AASLD poster 2015 ; NG T et al, CROI poster 2014; Liu R et al, AAC 2015 ; Lahser FC et al, AAC 2016 ; Muir AJ EASL presentation 2016 ; Bergfors et al, AVR 2016.
RAVN 2015 • Norwegian Institute of Public Health
43
Appendix A, HIV-1
Appendix A1. List of Surveillance Drug Resistance Mutations,SDRM, recommended by WHO.
HIV-1 RT and Protease Mutations For Drug Resistance Surveillance
NRTI Position M41 K65 D67 T69 K70 L74 V75 F77 Y115 F116 Q151 M184 L210 T215 K219
Mutation L R N, G, E D, Ins R, E V, I M, T, A, S L F Y M V, I W Y, F, I, S, C, D, V, E Q, E, N, R
NNRTI Position L100 K101 K103 V106 V179 Y181 Y188 G190 P225 M230
Mutation I E, P N,S M, A F C, I, V L, H, C A, S, E H L
PI Position L23 L24 D30 V32 M46 LI47 G48 I50 F53 I54 G73 L76 V82 N83 I84 I85 N88 L90
Mutation I I N I I V, A V, M V, L L, Y V, L, M, A, T, S S, T, C, A V A, T, F, S, C, M,L D V, A, C V D, S M
The following considerations were used to develop this list of drug resistance mutations* the mutations should cause or contribute to drug resistance, defined as being present on three or more of five expert lists of drug resistance mutations **. the mutations should not occur in untreated persons (i.e. they should be nonpolymorphic, and should not occur at highly polymorphic positions.), the mutation list should be applicable to all group M subtypes, and the mutation list should be simple, unambiguous, and parsimonious, excluding mutations resulting exceedingly rarely from drug pressure. * HIV-1 pretease and reverse transcriptase mutations for drug resistance surveillance, AIDS 2007, 21:215-223 Shafer R et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update, PLoS One 2009;4:e4724. Bennett DE et al. **ANRS drug resistance interpretation algorithm (2008.07),HIVdb drug resistance interpretation algorithm (4.3.7), IAS-USA Mutations Associated With Drug Resistance (March/April 2008), Los Alamos National Laboratories HIV Sequence database (2007), or Rega Institute Drug Resistance Interpretation Algorithm (7.1.1). The prevalence of all protease and RT mutations according to subtype and treatment can be found at http://hivdb.stanford.edu/cgi-bin/MutPrevBySubtypeRx.cgi.
www.fhi.no
Published by Norwegian Institute of Public HealthSeptember 2016P. O. Box 4404 NydalenNO-0403 OsloTel: 21 07 70 00
Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2015
RAVNResistensovervåking av virus i Norge Resistance against Antivirals in Norway
2016
RAVN 2015 omslag.indd 1 14.10.2016 15.39